Skip to content
Infinium Pharmachem logo

Infinium Pharmachem

INFINIUM NSE
₹271.60 −2.95 (−1.07%)
View as Markdown
MCP
Close 4 Nov 2026 ₹271.60 +6.60 +2.49% 1Y
Start ₹265.00

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
12.20%
Debt to Equity
0.19
EPS (TTM)
—
Book Value
₹77.68
Market Cap
—
P/E (TTM)
—
P/B
3.50
ROE
10.50%
Dividend Yield
0.00%
EBITDA
₹23.70 Cr
52W High
₹324.50
52W Low
₹189.40
Day Range
₹270.00 – ₹280.00
Volume
13,000

Peer Comparison

Healthcare › Pharmaceuticals

Infinium Pharmachem peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Infinium Pharmachem (this company)
₹271.60—₹433 Cr3.500.00%10.50%12.20%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%16.25%16.65%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

64 Good

Data confidence 84/100

surveillance:ESM1

Category scores

Quality
92
Strong
Returns, margins, earnings quality 22% weight
Valuation
44
Weak
Cheap vs sector & own history 24% weight
Growth
68
Strong
Sales & profit trajectory 9% weight
Financial Health
66
Strong
Solvency, leverage, coverage 9% weight
Momentum
87
Strong
Trend strength, vol-adjusted 12% weight
Ownership
69
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 14.0% over last 3 years.
  • Promoter holding has decreased over last 3 years: -8.14%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish847
OscillatorsBullish243
Moving AveragesStrong Bearish604

Key readings

RSI (14)
41.87
Neutral
MACD (12,26,9)
−2.18
Bearish
SMA (50)
279.60
Bearish
SMA (200)
229.14
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+21.76%
3Y+18.56%
1Y+21.79%

Net profit

Net profit growth by window
5Y+36.08%
3Y+11.87%
1Y+75.00%

Operating cash flow

Operating cash flow growth by window
5Y+37.18%
3Y+55.74%
1YTurned positive

Operating margin· change in pp

Operating margin growth by window
5Y+4.54 pp
3Y−2.46 pp
1Y−0.60 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹39.00 Cr
Mar 2021₹71.00 Cr
Mar 2022₹99.00 Cr
Mar 2023₹114 Cr
Mar 2024₹136 Cr
Mar 2025₹156 Cr
Mar 2026₹190 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹1.00 Cr
Mar 2021₹3.00 Cr
Mar 2022₹7.00 Cr
Mar 2023₹10.00 Cr
Mar 2024₹12.00 Cr
Mar 2025₹8.00 Cr
Mar 2026₹14.00 Cr

Half-yearly Results

₹ Cr
INFINIUM half-yearly results, ₹ crore
Particulars Sep 2022Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
79
61
74
83
73
84
106
Expenses
71
51
66
75
65
74
94
Operating Profit
9
10
8
8
8
10
11
OPM %
11%
17%
11%
10%
11%
12%
11%
Other Income
1
0
1
1
1
1
1
Interest
1
1
1
2
2
2
1
Depreciation
0
1
1
2
2
2
2
PBT
8
8
7
6
5
8
10
Tax %
22%
24%
24%
25%
41%
22%
19%
Net Profit
6
6
5
5
3
7
8
EPS (₹)
5.4
4.46
3.66
3.17
2.4
3.59
4.2

Profit & Loss

₹ Cr
INFINIUM profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
39
71
99
114
136
156
190
Expenses
36
66
89
98
117
136
168
Operating Profit
2
5
10
16
19
19
22
OPM %
6%
7%
10%
14%
14%
12%
11%
Other Income
1
1
1
1
2
−1
2
Interest
1
1
2
3
2
4
3
Depreciation
1
1
1
1
3
3
3
PBT
1
4
9
13
15
12
18
Tax %
30%
28%
23%
24%
24%
32%
20%
Net Profit
1
3
7
10
12
8
14
EPS (₹)
0.93
2.72
6.11
9.3
8.12
5.23
7.8
Div. Payout %
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
INFINIUM balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
5
14
16
16
Reserves
3
6
12
17
45
94
105
Borrowings
9
11
23
29
11
52
23
Other Liabilities
9
17
23
19
15
37
31
Total Liabilities
22
34
59
71
85
198
175
Fixed Assets
4
5
4
19
20
24
23
CWIP
0
4
8
0
0
1
8
Investments
0
0
0
0
0
29
29
Other Assets
18
26
46
52
66
144
114
Total Assets
22
34
59
71
85
198
175

Cash Flow

₹ Cr
INFINIUM cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3
7
12
9
−13
−29
34
Investing
−1
−5
−7
−5
−4
−27
−7
Financing
−1
−1
−2
−3
23
79
−32
Net Cash Flow
1
1
3
1
6
23
−5
Free Cash Flow
2
2
7
1
−17
−38
24
CFO/EBITDA
137
168
137
73
−51
−131
173

Ratios

INFINIUM financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
75
59
57
49
55
79
61
Inventory Days
84
62
78
89
87
137
96
Days Payable
82
79
56
31
16
38
10
Cash Conversion Cycle
76
43
78
108
126
178
146
Working Capital Days
46
12
25
27
96
97
99
ROCE %
—
32%
38%
36%
28%
15%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Infinium Pharmachem insights

65 extracted metrics across FY20–FY26.

Shareholding Pattern

As of Mar 2026

  • Promoters 64.91%
  • Public 31.96%
  • Others 2.91%
  • DIIs 0.22%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Infinium Pharmachem

What does Infinium Pharmachem Ltd do?
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates
Where is Infinium Pharmachem Ltd (INFINIUM) listed?
Infinium Pharmachem Ltd trades as INFINIUM on the NSE.
Which sector does Infinium Pharmachem Ltd belong to?
Infinium Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Infinium Pharmachem Ltd?
Over the last 52 weeks Infinium Pharmachem Ltd has traded between ₹189.4 and ₹324.5 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd reported a return on equity of 10.50%. Its debt-to-equity ratio is 0.19.

Company Information

Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates

Website infiniumpharmachem.com
Listed 17 Apr 2023
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INFINIUM.md for Infinium Pharmachem Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month